- Home
- EDRY vs INKT Comparison
EDRY vs INKT Comparison
Compare EDRY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- INKT
- Stock Information
- Founded
- EDRY 2018
- INKT 2017
- Country
- EDRY Greece
- INKT United States
- Employees
- EDRY N/A
- INKT N/A
- Industry
- EDRY Marine Transportation
- INKT Medicinal Chemicals and Botanical Products
- Sector
- EDRY Consumer Discretionary
- INKT Health Care
- Exchange
- EDRY Nasdaq
- INKT Nasdaq
- Market Cap
- EDRY 25.2M
- INKT 28.9M
- IPO Year
- EDRY N/A
- INKT 2021
- Fundamental
- Price
- EDRY N/A
- INKT $7.04
- Analyst Decision
- EDRY
- INKT Strong Buy
- Analyst Count
- EDRY 0
- INKT 2
- Target Price
- EDRY N/A
- INKT $37.50
- AVG Volume (30 Days)
- EDRY 7.8K
- INKT 14.7K
- Earning Date
- EDRY 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- EDRY N/A
- INKT N/A
- EPS Growth
- EDRY N/A
- INKT N/A
- EPS
- EDRY N/A
- INKT N/A
- Revenue
- EDRY $55,867,583.00
- INKT N/A
- Revenue This Year
- EDRY N/A
- INKT N/A
- Revenue Next Year
- EDRY $28.27
- INKT N/A
- P/E Ratio
- EDRY N/A
- INKT N/A
- Revenue Growth
- EDRY 10.25
- INKT N/A
- 52 Week Low
- EDRY $7.60
- INKT $4.56
- 52 Week High
- EDRY $24.73
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- EDRY 60.04
- INKT 47.56
- Support Level
- EDRY $9.15
- INKT $6.91
- Resistance Level
- EDRY $11.85
- INKT $7.51
- Average True Range (ATR)
- EDRY 0.58
- INKT 0.32
- MACD
- EDRY 0.09
- INKT -0.02
- Stochastic Oscillator
- EDRY 33.83
- INKT 27.28
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.